The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …

Context Obesity is responsible for an increased risk of sub-fecundity and infertility. Obese
women show poorer reproductive outcomes regardless of the mode of conception, and …

In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …

Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing
need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) …

Dysbiosis is associated with various diseases. The composition and diversity of gut
microbiota affect host physiology through the production of bioactive metabolites. Short …

The efficacy of Roux-en-Y gastric-bypass (RYGB) and other bariatric surgeries in the
management of obesity and type 2 diabetes mellitus and novel developments in …

As the prevalence of diabetes continues to climb, the number of individuals living with
diabetic complications will reach an unprecedented magnitude. The emergence of new …

Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2
diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully …